Web Research

What the Web Knows About Reckitt

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Bottom Line from the Web

The web reveals a company in the middle of a credibility test. FY2025 numbers (reported 5 March 2026) beat Reckitt's own 4–5% medium-term target and were paired with a $2.2bn special dividend, but the stock fell over 6% on hazy guidance — and was promptly punched another 7% lower on 22 April 2026 after Q1 2026 like-for-like revenue grew just 0.6%, well under consensus. Behind the noise is a more durable story the filings under-emphasise: an activist (Eminence Capital) prompted the 2024 strategic review, the $3.0bn (equity) Essential Home sale to Advent closed on 31 December 2025, and Mead Johnson's status — sale, retain, or distress — is now the single biggest swing factor for the equity, with Reuters reporting Danone has weighed an offer.

What Matters Most

1. Q1 2026 missed badly — recovery thesis is on probation

On 22 April 2026, Reckitt reported Q1 2026 group like-for-like revenue growth of just 0.6%, a full percentage point below consensus, and Core Reckitt LFL of 1.3% (vs. 1.78% expected). The stock fell as much as 7% to its lowest level since late 2024. Management warned of lower H1 margins citing high oil prices and a weak cold-and-flu season.

UBS noted three of four main categories underperformed expectations, with weakness in household and intimate wellness, while Europe and North America both lagged. AJ Bell's Russ Mould said CEO Kris Licht is "likely to come under greater scrutiny" and that the muted price reaction signals "healthy scepticism" over Reckitt's ability to meet full-year targets (Proactive, 22 Apr 2026; Reuters, 22 Apr 2026).

2. $2.2bn special dividend paid; Essential Home sale closed 31 Dec 2025

Reckitt sold a majority stake in Essential Home (laundry/surface care) to Advent International for an enterprise value of US$4.8bn (including debt), retaining a 30% equity stake in the acquisition vehicle. Shareholders approved a $2.2bn special dividend at $3.16 per share on 27 January 2026; payment was made on 20 February 2026. Total capital returned in 2025 was $3.1bn ([Reuters, 18 Jul 2025](https://www.reuters.com/en/reckitt-sells-essential-home-stake-advent-48-billion-2025-07-18/); [Proactive, 5 Mar 2026](https://www.proactiveinvestors.com/companies/news/1088383/reckitt-beats-its-own-targets-and-signals-confidence-in-2026-after-year-of-strategic-progress-1088383.html)).

This is the single largest piece of "skin moved" since the 2017 Mead Johnson deal and confirms that the 2024 portfolio-review thesis — provoked partly by activist Eminence Capital — has actual cash-return teeth, not just slide-deck rhetoric.

3. FY2025 was a quiet beat, but the market shrugged

On 5 March 2026, Reckitt reported Core Reckitt LFL net revenue growth of 5.2% — ahead of its 4–5% medium-term guidance — with adjusted operating margin up 40bps to 24.9%, adjusted EPS of $4.75 (+1.1%), free cash flow of $2.30bn (down 23.4% on restructuring/tax), and net debt of $8.83bn (1.6x EBITDA, vs 2.0x prior year). Despite the beat, shares fell more than 6% on the day as the market focused on cautious 2026 guidance (still 4–5% LFL). Emerging markets grew 14.6% LFL with double-digit growth in China, India, Indonesia and Colombia; Europe declined 1.4% (Reuters, 5 Mar 2026; Proactive, 5 Mar 2026).

4. Mead Johnson is the unfinished business — and Danone is reportedly circling

Reuters and Investing.com reporting (April 2026) noted Danone was considering acquiring Reckitt's Mead Johnson infant-formula unit. Top shareholders are pushing for a sale; CEO Licht said as far back as July 2024 he "would not rule out" a divestment while litigation is ongoing. AJ Bell's Russ Mould flagged that any sale "could provide a boost, though there is a good possibility that it would be a discounted price due to market uncertainty."

The 1 November 2024 jury verdict clearing Reckitt and Abbott of liability in a preterm-formula NEC case lifted a major overhang (shares +10% that day) and made an MJN exit cleaner (Reuters, 1 Nov 2024).

5. Sell-side is genuinely split — recent rating shifts in both directions

No Results

The 12-month consensus price target sits at $88.36 (Investing.com), with a range of $73.79–$102.88 — implying meaningful upside vs the post-Q1 share price near $62.48, but investors are treating that as an opinion not a promise (Investing.com; TipRanks via CNBC).

6. Activist Eminence Capital is the silent author of the strategic plan

Reuters reported on 21 May 2024 that activist Eminence Capital had built at least a 0.5% position in Reckitt. The July 2024 announcement to "offload homecare brands and consider options for nutrition" — which produced the Advent deal and the special dividend — followed within weeks, even though Reckitt has never publicly attributed the move to Eminence (Reuters, 21 May 2024).

7. Russia is still a live, awkward exposure

On 22 April 2026, Reuters reported Reckitt's Russian unit is **developing local products and registering IP** to replace the majority of its hygiene portfolio in response to harsher EU sanctions — confirming Reckitt has not exited Russia despite the 2022 announcement and is actively re-engineering products to keep the business running ([Reuters, 22 Apr 2026](https://www.reuters.com/business/reckitts-russia-unit-develops-new-local-products-after-eu-sanctions-harden-2026-04-22/)).

8. Trade-war exposure: Reckitt is more vulnerable than peers

A Reuters analysis from 17 March 2025 flagged that Reckitt may be forced to raise US prices or absorb costs because its low US manufacturing capacity leaves it more exposed to tariffs than P&G or Unilever. This was cited again in the April 2026 margin warning (Reuters, 17 Mar 2025).

9. The 2024 Middle East accounting incident still casts a shadow

On 28 February 2024, Reckitt disclosed an investigation that found employees had under-reported liabilities in the Middle East. The shares posted their biggest one-day drop since December 1999. This is the trigger event for the wave of US securities-class-action notices (Gross Law Firm, Portnoy Law Firm — Aug 2025) that name Narasimhan, Carr, Durante, Licht and Sly as defendants (Reuters, 28 Feb 2024).

10. Credit profile: Moody's A3 stable, leverage well within target

Moody's reaffirmed Reckitt's A3 rating with stable outlook on 20 March 2025, expecting gross debt/EBITDA at or below 2.5x. FY2025 net debt/adj EBITDA of 1.6x sits comfortably inside that envelope, even after the $2.2bn special dividend (Investing.com / Moody's, 20 Mar 2025).

Recent News Timeline

No Results

What the Specialists Asked

Insider Spotlight

No Results

Kris Licht (CEO, since October 2023) — Total annual compensation ~$4.87m, 16% salary / 84% bonus & equity. Owns 0.005–0.012% of the company directly. The 21 March 2026 sale at $69.71 ($264,866) came roughly a month before the 22 April 2026 Q1 miss that took the shares to $62.48 — a small absolute amount but the timing is notable for a CEO whose turnaround thesis is on probation.

Shannon Eisenhardt (CFO) — Received deferred-share grant of 10,328 ordinary shares in March 2026. Co-presenting with Licht at CAGNY 2026.

Jeremy Darroch (Chair, since May 2024) — Former Sky CEO, also a director of The Walt Disney Company and ex-M&S board member. Replaced Chris Sinclair after 9 years.

Harry Kirsch & Deepak Nath (NEDs, 1 April 2026) — Kirsch is CFO of Novartis Pharma AG; Nath is CEO of Smith+Nephew plc. Both appointments dial up healthcare/pharma DNA on a board increasingly oriented toward "Core Reckitt" as a Self-Care + Germ-Protection + MJN nutrition franchise.

Activist context — Eminence Capital's >0.5% stake (May 2024) preceded the homecare disposal and capital return. No public 13D-style demand was filed; the influence is inferred from the timing of strategic actions.

Rank-and-file ownership — Insiders combined own under 1% of the company (about $6.5m). For a $40bn enterprise that is low; investors should not over-weight insider-buy/sell signals from such a small float.

Industry Context

Private-label squeeze in developed markets. Reuters reporting (3 Jun 2025; 23 Apr 2025) repeatedly notes that consumer-staples giants — Reckitt, P&G, Unilever — face structural pressure from cheaper own-label brands that gained share during COVID. AJ Bell's Russ Mould flagged this explicitly in April 2026 as a risk to Lemsip and Strepsils volumes. Reckitt's Europe segment declined 1.4% LFL in 2025 versus emerging markets at +14.6%.

Trade-war / tariff exposure. Per Reuters (17 March 2025), Reckitt is structurally more exposed than P&G or Unilever to US tariffs because of low US manufacturing capacity. The April 2026 margin warning citing "high oil prices" is partly a proxy for surfactant and petrochemical input cost pressure that disproportionately affects Reckitt's Lysol/Finish/Vanish supply chains.

Emerging markets as the growth engine. China, India, Indonesia, Colombia all delivered double-digit growth for Reckitt in 2025; emerging markets were 42% of Core Reckitt net revenue in Q3 2025 (Reuters). JPMorgan's Celine Pannuti flagged in April 2026 that "Reckitt's expectation for second-quarter emerging markets performance to mirror the first quarter was disappointing, given the region has driven growth for its core business." This is the new central bull/bear axis.

Sector M&A activity. The Advent–Essential Home transaction at $4.8bn EV is a high-profile precedent for further consumer-staples carve-outs. Danone's reported interest in Mead Johnson would, if real, be the second multi-billion deal involving Reckitt in less than 18 months — a clear signal that the structural reorganisation of large household/health-staples portfolios remains in early innings.

Generated Apr 28, 2026 06:29 UTC